中医药与化疗结合治疗肺癌临床观察

A Study on Treatment of Lung Cancer by Combined Therapy of Traditional Chinese Medicine and Chemotherapy

本研究将１０２例肺癌患者随机分为两组。Ａ组（化疗＋中药）及８组（单用化疗）所用化疗方案大致相同。Ａ组所用中药遵循辨证论治分为肺脾气虚、肺热痰湿、肺胃阴虚和气滞血瘀型。治疗结果：Ａ组和Ｂ组总有效率按ＷＨＯ标准分别为５２．１％和３５．２％（Ｐ＞０．０５）；１年存活率分别为６９．４％和６６．７％（Ｐ＞０．０５）；２年存活率分别为５６．３％和１５．８％（Ｐ＜０．０５）；在观察期内已死亡的患者中，中位生存期分别为１３个月和９个月。结果提示Ａ组患者中位生存期及２年以上生存期的延长可能与中医药的疗效密切相关，但中药与化疗结合未能明显提高治疗有效率。

From May 1992 to May 1995, 102 patients with lung cancer were divided randomly into two groups: group A, 48 patients, treated with combined therapy of TCM and chemotherapy, group B, 54 patients treated with chemotherapy alone. The protocol of chemotherapy used in the two groups was similar. The Chinese medicines were given according mainly to the Syndrome Differentiation. Four types were found in the group A: the Lung and Spleen Qi Deficiency type, the Lung Heat and Phlegm-Dampness type, the Lung-Yin and Stomach-Yin Deficiency type and the Qi stagnation and blood stasis type. The total effective rate according to the WHO standard was as follows: that of group A and group B was 52.1% and 35.1%; the 1 year survival rate of them was 69.4% and 66.7%, the 2 year survival rate was 56.2% and 15.8% and the median survival time were 13 months and 9 months, respectively. These results suggest that the elevation of median survival time and 2 year survival rate of group A might be closely related with the therapeutic effect of TCM,but the combined therapy of TCM and chemotherapy did not improve the therapeutic efficacy significantly.